BioCentury
ARTICLE | Clinical News

Merck's evobrutinib meets in Phase IIb for MS

March 9, 2018 5:15 PM UTC

Merck KGaA (Xetra:MRK) said evobrutinib (M2951, MSC2364447C) met the primary endpoints of reducing the total number of gadolinium-enhancing T1 lesions from baseline to weeks 12, 16, 20 and 24 vs. placebo in a Phase IIb trial to treat relapsing multiple sclerosis. The company could not be reached for details or next steps...

BCIQ Company Profiles

Biogen Inc.

Merck KGaA

BCIQ Target Profiles

Bruton's tyrosine kinase